ClinicalTrials.gg
Active, not recruitingNCT06194448NEOLAUpdated Aug 19, 2026

To Evaluate the Efficacy/Safety of Osimertinib Prior to CRT and Maintenance of it With Stage III, Unresectable NSCLC With EGFR Mutations

A Phase 2 interventional study of Osimertinib and Cisplatin or Carboplatin; Pemetrexed or Paclitaxel in Lung Cancer, sponsored by AstraZeneca. Active, not recruiting at 39 sites in 9 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2026-08-19.

Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
76
Allocation
Not applicable
Ages
18 Years to 130 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 30 studies testing osimertinib in Lung Neoplasms — 10 open to participants now, 18 under way, 2 of them phase 3. osimertinib · Lung Neoplasms.

Enrollment
12th of 30
76 · median 52
Started
2024
with 4 others
Phase 2
16 of 30
5 open now
Primary completion
2026-07
later than 6 of 17 live
Registered
22nd of 30
by date
Lead sponsor
10 of 30
AstraZeneca

Among the 30 studies testing osimertinib in Lung Neoplasms, this one is the 12th largest by enrollment, is one of 5 that started in 2024, is one of 16 in phase 2, reaches primary completion later than 6 of the 17 other live ones, and was the 22nd registered.

Lung Neoplasms

5,424 studies on the registry are indexed under Lung Neoplasms; 1,345 are open to participants now.

Browse Lung Neoplasms studies →

Open to participants now

10 of the 30 studies testing osimertinib in Lung Neoplasms are open now, in 3 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 10 open studies →

About osimertinib

osimertinib: first FDA approval 2015 (TAGRISSO), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 995 Lung Neoplasms studies recruiting now, 682 (69%) set no upper age limit and 142 (14%) stop at 75 or younger; 45 take children under 18; 142 take healthy volunteers.

This study: 18 Years to 130 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies testing osimertinib in Lung Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to measure efficacy and safety of osimertinib as induction therapy prior to curative intent CRT and maintenance osimertinib in adult patients with Stage III, unresectable NSCLC with common EGFR mutations (exon 19 deletion or L858R).

Read the detailed description

The study duration will be approximately 2 years for recruitment and 2 years of follow-up from the last patient's initiation into the study.

The induction treatment with osimertinib will be up to 8 weeks, followed by 6 weeks of CRT treatment and osimertinib maintenance treatment until PD or death.

The visit frequency will be every 2 weeks to 4 weeks during the induction treatment period, every 3 weeks during the CRT period (every 3 weeks for chemotherapy and daily visits for RT), and every 12 weeks during the osimertinib maintenance treatment period.

03

Conditions studied

  • Lung Cancer

Browse trials for

Keywords

  • EGFR +
  • Unresectable Non-small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients must be 18 or the legal age of consent in the jurisdiction in which the study is taking place, at the time of signing the form.
  2. Patients with documented NSCLC of predominantly non-squamous, squamous, and adenosquamous pathology who present with locally advanced, unresectable (Stage III) disease (according to Version 8 of the IASLC Staging Manual in Thoracic Oncology). It is recommended but not required that except for overt cT4 disease, nodal status N2, or N3 should have been proven by , via endobronchial ultrasound, mediastinoscopy, thoracoscopy, or in absence of biopsy, should have been confirmed with whole body 18FDG PET plus contrast-enhanced CT in addition to or in combination with PET.
  3. Patient who are eligible for and - planning to undergo CCRT or SCRT treatment.
  4. Patients who had recurred from Stage I/II/III after complete surgery or had gross incomplete resections can be included if they didn't receive treatment with any chemotherapy, radiation therapy, immunotherapy, targeted therapy, or agents.
  5. Patients with are only eligible for inclusion if they meet all the following criteria:

    • Demonstrate absence of co-infection or history of HCV co-infection
    • Demonstrate absence of co-infection
    • Patients with active HBV infection are eligible if they are:

      • Receiving anti-viral treatment for at least 6 weeks prior to study treatment, HBV DNA is suppressed to \<100 IU/mL and transaminase levels are below .

    Participants with a resolved or chronic HBV infection are eligible if they are:

    • Negative for HBsAg and positive for hepatitis B core antibody [anti-HBc IgG or total anti-HBc Ab]. In addition, patients should be referred to a local hepatologist and treated as per local guidelines or
    • Positive for HBsAg, but for > 6 months have had transaminases levels below ULN and HBV DNA levels below \<100 IU/mL or below the detectable limit of locally available test kit (i.e., are in an inactive carrier state). In addition, patients must be receiving anti-viral prophylaxis for 2-4 weeks prior to study treatment.
  6. Patients with HIV are only eligible for inclusion if they meet all the following criteria:

    • Demonstrate absence of HBV/ HCV co-infection
    • Undetectable viral RNA load for 6 months
    • of >350 cells/μL
    • No history of AIDS-defining opportunistic infection within the past 12 months
    • Stable for at least 4 weeks on the same anti-HIV medications
  7. Availability of the EGFRm test results confirming that the tumour harbours one of the two common EGFR mutations known to be associated with EGFR-TKI sensitivity (Ex19del, L858R), either alone or in combination with other EGFR mutations including de novo T790M
  8. of 0 or 1 with no deterioration over the previous 2 weeks prior to baseline at screening and prior to first dose.
  9. Minimum of > 12 weeks at Day 1.
  10. At least one lesion that can be accurately measured at baseline as ≥ 10 mm in the longest diameter (except lymph nodes, which must have short axis ≥ 15 mm) with CT or MRI and is suitable for accurate repeated measurements.
  11. Male and/or female. use by males or females should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies and/or SoC CRT
  12. Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the ICF and in this CSP.
  13. Provision of signed and dated written Optional Genomics Initiative Research Information and Consent Form prior to collection of samples for optional genomics initiative research that supports the Genomic Initiative.

Note: If a patient declines to participate in optional genetic research, there will be no penalty or loss of benefit to the patient, and he/she will not be excluded from other aspects of the study.

Exclusion criteria

Exclusion Criteria:

  1. Any presence of small cell and mixed small-cell and non-small cell histology.
  2. Past medical history of ILD/pneumonitis, drug-induced ILD, radiation pneumonitis that required treatment, or any evidence of clinically active ILD/pneumonitis.
  3. Any unresolved toxicities from prior therapy greater than Grade 1 at the time of starting study treatment with the exception of alopecia and Grade 2 prior platinum-therapy related neuropathy. Patients with irreversible toxicity that is not reasonably expected to be exacerbated by study intervention in the opinion of the investigator may be included after consultation with the AstraZeneca medical monitor (eg, hearing loss).
  4. Any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension and active bleeding diatheses, which in the investigator's opinion makes it undesirable for the patient to participate in the trial or which would jeopardise compliance with the protocol, or active infection (eg, patients receiving treatment for infection, including , , and tuberculosis) or active uncontrolled infection.
  5. nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product or previous significant bowel resection that would preclude adequate absorption of osimertinib.
  6. History of another primary except for malignancy treated with curative intent with no known active disease ≥ 2 years before the first dose of study intervention and of low potential risk for recurrence. Exceptions include adequately resected non-melanoma skin cancer and curatively treated in situ disease. Patients who have received RT with overlapping fields (eg, cured breast cancer) should be excluded.
  7. Patient meets any of the following cardiac criteria:

    1. Mean resting > 470 msec, obtained from 3 ECGs, using the screening clinic machine-derived QTc value.
    2. Any abnormalities in rhythm, conduction or morphology of resting ECG eg, complete left bundle branch block, third degree heart block and second-degree heart block. Patients with atrial fibrillation controlled by medication or arrhythmias controlled by pacemakers may be permitted based on the investigator judgement with cardiologist consultation recommended.
    3. History of QT prolongation associated with other medications that required discontinuation of that medication.
  8. Congenital long QT syndrome, family history of long QT syndrome, unexplained sudden death under 40 years of age in first-degree relatives or patients with any factors that increase the risk of QTc prolongation/arrhythmic events such as electrolyte abnormalities, heart failure or any concomitant medication known to prolong the QT interval and cause TdP.
  9. Inadequate bone marrow reserve or organ function as demonstrated by any of the following laboratory values:

    • \<1.5 × 10\^9/L
    • count \<100 × 10\^9/L
    • \<90 g/L
    • Alanine transferase >2.5 times the (ULN)
    • Aspartate transferase >2.5 times ULN
    • Total >1.5 times ULN or >3 times ULN in the presence of documented Gilbert's Syndrome (unconjugated hyperbilirubinaemia)
    • Creatinine >1.5 times ULN concurrent with \<50 mL/min (measured or calculated by Cockcroft and Gault formula); confirmation of creatinine clearance is only required when creatinine is >1.5 times ULN.
  10. Patients currently receiving (or unable to stop use prior to receiving the first dose of study treatment) medications or herbal supplements known to be strong inducers of (at least 3-week prior to dosing). All patients must try to avoid concomitant use of any medications, herbal supplements and/or ingestion of foods with known inducer effects on CYP3A4.
  11. Prior treatment with any chemotherapy, radiation therapy, immunotherapy or agents for locally advanced, unresectable Stage III NSCLC. Prior surgical resection (ie, Stage I, II, or III) with no systemic treatment with residual disease or a recurrence is permitted.
  12. Prior exposure to EGFR-TKI therapy
  13. Major surgical procedure (excluding placement of vascular access) or significant traumatic injury within 4 weeks of the first dose of study intervention or an anticipated need for major surgery during the study.
  14. Participation in another clinical study with a study intervention or investigational medicinal device administered in the last 4 weeks (unless the safety profile is known prior to first dose of study intervention), or concurrent enrolment in another clinical study (unless the study is observational [noninterventional], or the patient is in the followup period of an interventional study).
  15. History of to active or inactive of osimertinib or drugs with a similar chemical structure or class to osimertinib.
  16. History of hypersensitivity to active or inactive excipients of the chemotherapy regimen of choice (pemetrexed or paclitaxel; cisplatin or carboplatin) or RT or drugs with a similar chemical structure or class to the chemotherapy.
  17. Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site).
  18. Judgment by the investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions, and requirements.
  19. Previous enrolment in the present study. Rescreening of individuals who were screen failures is allowed.
  20. For females only: Currently pregnant (confirmed with positive pregnancy test) or breastfeeding.
  21. Patients should refrain from breastfeeding from enrolment throughout the study and until 6 weeks after last dose of study intervention.
  22. In addition, the following are considered criteria for exclusion from the exploratory genetic research:

    • Prior bone marrow transplant.
    • Non-leukocyte depleted whole blood transfusion within 120 days of genetic sample collection.
Terms in these criteria, in plain language(28)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
76 participants (actual)

Study arms

  • Experimental
    Open-Label Osimertinib Induction Treatment

    Patients will receive open-label osimertinib induction treatment for 8 weeks (± 1 week window to account for patient variability and CRT scheduling), followed by CRT treatment for 6 weeks (± 1 week) and then osimertinib maintenance treatment until RECIST 1.1-defined radiological progression by investigator unless there is evidence of unacceptable toxicity or if the patient requests to stop the study treatment.

    Drug: Osimertinib · Drug: Cisplatin or Carboplatin; Pemetrexed or Paclitaxel · Drug: Radiation

Interventions

  • 80 mg daily (or 40 mg daily for dose reduction)

    Also known as: Tagrisso, AZD9291

  • DrugCisplatin or Carboplatin; Pemetrexed or Paclitaxel

    Pemetrexed (500 mg/m2 to be administered on Day 1 of every 3-week cycle for 2 cycles) or Paclitaxel (175 mg/m2 on Day 1 of every 3-week cycle for 2 cycles) PLUS Cisplatin (75 mg/m2) or Carboplatin (AUC5) to be administered on Day 1 of every 3--week cycle for 2 cycles

  • DrugRadiation

    Patients must have received a total dose of radiation of 60 Gy ± 10% (54 to 66 Gy) as part of the chemoradiation therapy. It is recommended but not required that patients have a: * Mean lung dose \< 20 Gy and/or V20 \< 35% * Mean oesophagus dose \< 34 Gy * Heart V50 \< 25%, V30 \< 50%, and V45 \< 35%

06

What researchers measure

Primary outcomes

  1. PFS (Progression-Free Survival)

    PFS is defined as the time from date of first dose until progression per RECIST 1.1 as assessed by the investigator at the local site, or death due to any cause.

    Time frame: Assessed from date of first dose to progression (up to a maximum of approximately 4 years)

Secondary outcomes

  1. ORR (Objective Response Rate)

    ORR is defined as the proportion of patients who have a CR or PR, as determined by the investigator at local site per RECIST 1.1.

    Time frame: Assessed during the induction phase of the study, scans are carried out at baseline and week 8 (plus or minus visit window).

  2. DCR (Disease Control Rate)

    DCR is defined as the percentage of subjects who have a best overall response of CR or PR or SD (at 8 weeks) as determined by the investigator at the local site per RECIST 1.1.

    Time frame: Assessed during the induction phase of the study, scans are carried out at baseline and week 8 (plus or minus visit window).

  3. OS (Overall Survival)

    OS is defined as time from date of first dose until the date of death due to any cause.

    Time frame: Assessed from first dose to end of study or death (up to a maximum of approximately 4 years)

  4. EFS (Event-Free Survival)

    EFS is defined as time from date of first dose until any of the following events: progression of disease that precludes CRT or completion of CRT, progression during or after CRT, or death due to any cause.

    Time frame: Assessed from first dose until a progression event or death (up to a maximum of approximately 4 years)

Other outcomes

  1. AEs

    To assess the safety of osimertinib used as an induction therapy prior to CRT and maintenance osimertinib treatment by assessment of AEs in patients with unresectable EGFRm NSCLC

    Time frame: from signing ICF to 28 days after last dose or end of study (up to a maximum of approximately 4 years)

07

Study locations

39 sites
  • Research Site
    La Jolla, California 92093, United States
  • Research Site
    Palo Alto, California 94304, United States
  • Research Site
    Beijing, 100021, China
  • Research Site
    Changsha, 410013, China
  • Research Site
    Guangzhou, 510060, China
  • Research Site
    Hangzhou, 310022, China
  • Research Site
    Harbin, 150081, China
  • Research Site
    Hefei, 230001, China
  • Research Site
    Jinan, 250117, China
  • Research Site
    Nanning, 530021, China
  • Research Site
    Shanghai, 200032, China
  • Research Site
    Tianjin, 300060, China
  • Research Site
    Wuhan, 430022, China
  • Research Site
    Wuhan, 430071, China
  • Research Site
    Zhengzhou, 450052, China
  • Research Site
    Haifa, 31096, Israel
  • Research Site
    Jerusalem, 91031, Israel
  • Research Site
    Tel Aviv, 62748, Israel
  • Research Site
    Cheongju-si, 28644, South Korea
  • Research Site
    Seongnam-si, 13620, South Korea
  • Research Site
    Seoul, 03080, South Korea
  • Research Site
    Seoul, 03722, South Korea
  • Research Site
    Seoul, 06351, South Korea
  • Research Site
    Suwon, 16247, South Korea
  • Research Site
    Barcelona, 08003, Spain
  • Research Site
    Donostia / San Sebastian, 20014, Spain
  • Research Site
    Granada, 18016, Spain
  • Research Site
    Madrid, 28007, Spain
  • Research Site
    Tainan, 704, Taiwan
  • Research Site
    Taipei, 11217, Taiwan
  • Research Site
    Bangkok, 10210, Thailand
  • Research Site
    Bangkok, 10330, Thailand
  • Research Site
    Chiang Rai, 57000, Thailand
  • Research Site
    Hat Yai, 90110, Thailand
  • Research Site
    Khon Kaen, 40002, Thailand
  • Research Site
    Ankara, 06010, Turkey (Türkiye)
  • Research Site
    Yenimahalle, 06560, Turkey (Türkiye)
  • Research Site
    Hanoi, 100000, Vietnam
  • Research Site
    Ho Chi Minh City, 700000, Vietnam
08

References and documents

Publications

  • Aredo JV, Peled N, Arriola E, Wakelee H, Ahn MJ, Kwint MH, Taylor R, van der Gronde T, Nasirova F, Chen M. Osimertinib before and after chemoradiotherapy for unresectable stage III EGFR-mutated NSCLC: NEOLA Trial Protocol. Future Oncol. 2025 Dec;21(29):3731-3737. doi: 10.1080/14796694.2025.2587569. Epub 2025 Nov 14. PubMed 41236484 ↗

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual participant-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2024 to primary completion in Jul 2026, 26 months.

Of 77 industry-sponsored phase 2 interventional studies under Lung Neoplasms, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 61. This study's 26 months is below that.

Counting every sponsor, half of 364 studies reached it within 65 months; a quarter within 34 and three quarters within 105.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 20, 2023
First posted
Jan 8, 2024
StartActual
Apr 21, 2024
Primary completionActual
Jul 7, 2026
CompletionEst.
Jul 7, 2027
Last update
Aug 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06194448
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Jan 8, 2024
Start date
Apr 21, 2024
Primary completion
Jul 7, 2026
Completion
Jul 7, 2027 (estimated)
Last update
Aug 19, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Osimertinib

Start the discussion